E
Elke Langkopf
Researcher at Boehringer Ingelheim
Publications - 143
Citations - 3891
Elke Langkopf is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Xanthine & Bicyclic molecule. The author has an hindex of 36, co-authored 143 publications receiving 3846 citations. Previous affiliations of Elke Langkopf include Neurocrine Biosciences.
Papers
More filters
Journal ArticleDOI
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
TL;DR: Investigation of the potency, selectivity, mechanism, and duration of action of BI 1356 in vitro and in vivo and compared it with other DPP-4 inhibitors found it to have the potential to become the first truly once-a-day D PP-4 inhibitor for the treatment of type 2 diabetes.
Journal ArticleDOI
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Matthias Eckhardt,Elke Langkopf,Michael Mark,Moh Tadayyon,Leo Thomas,Herbert Nar,Waldemar Pfrengle,Brian Guth,Ralf Lotz,Peter Sieger,Holger Fuchs,Frank Himmelsbach +11 more
TL;DR: 1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species, is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.
Patent
8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
Frank Himmelsbach,Elke Langkopf,Matthias Eckhardt,Michael Mark,Roland Maier,Ralf Lotz,Mohammad Tadayyon +6 more
TL;DR: In this paper, the authors proposed substituted xanthines of general formula (I) wherein R 1 to R 3 have the designations cited in patent claims 1 to 16, and to the tautomers, stereoisomers, mixtures, prodrugs and salts thereof, which have precious pharmacological properties.
Journal ArticleDOI
beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition.
Andreas Eger,Andreas Stockinger,John Edward Park,Elke Langkopf,Mario Mikula,Josef Gotzmann,Josef Gotzmann,Wolfgang Mikulits,Hartmut Beug,Roland Foisner +9 more
TL;DR: Results demonstrate that loss of E-cadherin can contribute to increased LEF/TCF-β-catenin signalling, which in turn cooperates with autocrine TGFβ signalling to maintain an undifferentiated mesenchymal phenotype.
Patent
Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
Hauel Norbert,Frank Himmelsbach,Elke Langkopf,Matthias Eckhardt,Roland Maier,Michael Mark,Mohammad Tadayyon,Iris Kauffmann-Hefner +7 more
TL;DR: In this article, the authors defined substituted imidazo-pyridinones of general formula (I) as in Claim, the tautomers thereof, the stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties.